TY - JOUR
T1 - Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease
AU - Rembach, Alan
AU - Faux, Noel G.
AU - Watt, Andrew D.
AU - Pertile, Kelly K.
AU - Rumble, Rebecca L.
AU - Trounson, Brett O.
AU - Fowler, Christopher J.
AU - Roberts, Blaine R.
AU - Perez, Keyla A.
AU - Li, Qiao Xin
AU - Laws, Simon M.
AU - Taddei, Kevin
AU - Rainey-Smith, Stephanie
AU - Robertson, Joanne S.
AU - Vandijck, Manu
AU - Vanderstichele, Hugo
AU - Barnham, Kevin J.
AU - Ellis, Kathryn A.
AU - Szoeke, Cassandra
AU - MacAulay, Lance
AU - Rowe, Christopher C.
AU - Villemagne, Victor L.
AU - Ames, David
AU - Martins, Ralph N.
AU - Bush, Ashley I.
AU - Masters, Colin L.
PY - 2014/1
Y1 - 2014/1
N2 - Background: A practical biomarker is required to facilitate the preclinical diagnosis of Alzheimer's disease (AD). Methods: Plasma amyloid beta (Aβ)1-40, Aβ1-42, Aβn-40, and Aβn-42 peptides were measured at baseline and after 18 months in 771 participants from the Australian Imaging Biomarkers and Lifestyle (AIBL) study of aging. Aβ peptide levels were compared with clinical pathology, neuroimaging and neuropsychological measurements. Results: Although inflammatory and renal function covariates influenced plasma Aβ levels significantly, a decrease in Aβ1-42/Aβ1-40 was observed in patients with AD, and was also inversely correlated with neocortical amyloid burden. During the 18 months, plasma Aβ1-42 decreased in subjects with mild cognitive impairment (MCI) and in those transitioning from healthy to MCI. Conclusion: Our findings are consistent with a number of published plasma Aβ studies and, although the prognostic value of individual measures in any given subject is limited, the diagnostic contribution of plasma Aβ may demonstrate utility when combined with a panel of peripheral biomarkers.
AB - Background: A practical biomarker is required to facilitate the preclinical diagnosis of Alzheimer's disease (AD). Methods: Plasma amyloid beta (Aβ)1-40, Aβ1-42, Aβn-40, and Aβn-42 peptides were measured at baseline and after 18 months in 771 participants from the Australian Imaging Biomarkers and Lifestyle (AIBL) study of aging. Aβ peptide levels were compared with clinical pathology, neuroimaging and neuropsychological measurements. Results: Although inflammatory and renal function covariates influenced plasma Aβ levels significantly, a decrease in Aβ1-42/Aβ1-40 was observed in patients with AD, and was also inversely correlated with neocortical amyloid burden. During the 18 months, plasma Aβ1-42 decreased in subjects with mild cognitive impairment (MCI) and in those transitioning from healthy to MCI. Conclusion: Our findings are consistent with a number of published plasma Aβ studies and, although the prognostic value of individual measures in any given subject is limited, the diagnostic contribution of plasma Aβ may demonstrate utility when combined with a panel of peripheral biomarkers.
KW - Alzheimer's disease
KW - Amyloid-β
KW - Biomarkers
KW - Diagnosis
KW - Pittsburgh compound B
KW - Positron emission tomography
UR - http://www.scopus.com/inward/record.url?scp=84891163157&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2012.12.006
DO - 10.1016/j.jalz.2012.12.006
M3 - Article
C2 - 23491263
AN - SCOPUS:84891163157
VL - 10
SP - 53
EP - 61
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
SN - 1552-5260
IS - 1
ER -